{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460017787
| IUPAC_name = (3β)-3-[(3-carboxypropanoyl)oxy]-11-oxoolean-12-en-30-oic acid<br>OR<br>(2''S'',4a''S'',6a''S'',6b''R'',8a''R'',10''S'',12a''S'',12b''R'',14b''R'')-10-(3-carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
| image = Carbenoxolone.png
| alt = Skeletal formula of carbenoxolone
| width = 270
| image2 = Carbenoxolone 3D ball.png
| alt2 = Ball-and-stick model of the carbenoxolone molecule
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|carbenoxolone}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =

<!--Identifiers-->
| IUPHAR_ligand = 4151
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 5697-56-3
| ATC_prefix = A02
| ATC_suffix = BX01
| ATC_supplemental =  
| PubChem = 636403
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB02329
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 552190
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MM6384NG73
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 499915

<!--Chemical data-->
| C=34 | H=50 | O=7 
| molecular_weight = 570.765 g/mol
| smiles = O=C(O)CCC(=O)O[C@H]4CC[C@@]3([C@H]5C(=O)/C=C2/[C@@H]1C[C@](C(=O)O)(C)CC[C@]1(C)CC[C@]2([C@@]5(CC[C@H]3C4(C)C)C)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OBZHEBDUNPOCJG-WBXJDKIVSA-N
}}

'''Carbenoxolone '''('''CBX''') is a [[glycyrrhetinic acid]] derivative with a steroid-like structure, similar to substances found in the root of the [[Glycyrrhiza glabra|licorice plant]]. Carbenoxolone is used for the treatment of peptic, esophageal and oral [[ulcer]]ation and inflammation. Electrolyte imbalance is a serious side effect of carbenoxolone when used systemically.<ref>{{Cite journal|title = Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures | pmc=3316363 | pmid=22473546 | doi=10.5698/1535-7511-12.2.66 | volume=12 | issue=2 | year=2012 | journal=Epilepsy Curr | pages=66–8 | vauthors=Connors BW}}</ref>

Carbenoxolone reversibly inhibits the conversion of [[cortisol]] to the inactive metabolite [[cortisone]] by blocking [[11β-hydroxysteroid dehydrogenase]] (11β-HSD). 11β-HSD also reversibly catalyzes the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol.<ref>{{Cite web|url = https://pubchem.ncbi.nlm.nih.gov/compound/46936354?from=summary#section=DrugBank-Interactions|title = PubChem Compound|date = |accessdate = |website = |publisher = }}</ref><ref>{{Cite web|url = https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Aldrich/Product_Information_Sheet/c4790pis.pdf|title = Sigma-Aldrich|date = |accessdate = |website = |publisher = }}</ref>

Carbenoxolone is a modestly potent, reasonably effective, water-soluble blocker of [[gap junctions]].<ref>{{Cite journal|title = Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures | pmc=3316363 | pmid=22473546 | doi=10.5698/1535-7511-12.2.66 | volume=12 | issue=2 | year=2012 | journal=Epilepsy Curr | pages=66–8 | vauthors=Connors BW}}</ref>

Carbenoxolone has also been used in topical creams such as Carbosan gel, marketed for treatment of lip sores and mouth ulcers.

==Nootropic effects==
Carbenoxolone has also been investigated for [[nootropic]] effects.<ref name="pmid15071189">{{cite journal |vauthors=Sandeep TC, Yau JL, MacLullich AM |title=11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=101 |issue=17 |pages=6734–9 |year=2004 |pmid=15071189 |doi=10.1073/pnas.0306996101 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=15071189 |pmc=404114|display-authors=etal}}</ref> This research started from an observation that long-term exposure to [[glucocorticoid]]s may have negative effects on cognition. Carbenoxolone may decrease the amount of active glucocortocoid in the brain, because the drug inhibits 11β-HSD, an enzyme which regenerates [[cortisol]], an active glucocorticoid, from inactive [[cortisone]].

In the research trial investigating this use of carbenoloxone, it was shown that the drug improved verbal fluency in elderly healthy men (aged 55–75). In type 2 diabetics aged 52–70, the drug improved verbal memory. However, [[potassium-sparing diuretic]] [[amiloride]] was co-administered with carbenoxolone, since carbenoxolone used by itself may cause [[hypertension]] by increasing cortisol in the kidneys.

==See also==
* [[11α-Hydroxyprogesterone]]

==References==
{{Reflist|2}}

{{Drugs for peptic ulcer and GORD}}
{{Nootropics}}
{{Glucocorticoidics}}

[[Category:11β-Hydroxysteroid dehydrogenase inhibitors]]
[[Category:Drugs acting on the gastrointestinal system and metabolism]]
[[Category:Nootropics]]
[[Category:Carboxylate esters]]
[[Category:Ketones]]
[[Category:Triterpenes]]

[[ru:Противоязвенные препараты и препараты для лечения гастроэзофагеального рефлюкса#Карбеноксолон]]